Table 1.

Clinico-pathologic characteristics and PGA for African-American cohort (copy-number alteration data available for n = 205 of 220 patients).

VariableAA (n = 205)
Median PSA, ng/mL (IQR)7.30 (5.24–13.00)
Median age, year (IQR)58 (53–63)
Clinical T stage, n (%)
 T1c154 (75.1)
 T2a34 (16.6)
 T2b/c17 (8.3)
Biopsy grade group, n (%)
 1 (GS 6)72 (35.1)
 2 (GS 3+4)49 (23.9)
 3 (GS 4+3)48 (23.4)
 4 (GS 8)26 (12.7)
 5 (GS 9–10)10 (4.9)
RP grade group, n (%)
 1 (GS 6)28 (13.7)
 2 (GS 3+4)32 (15.6)
 3 (GS 4+3)91 (44.4)
 4 (GS 8)33 (16.1)
 5 (GS 9–10)21 (10.2)
Pathologic T stage, n (%)
 T2N087 (43.1)
 T3aN071 (35.2)
 T3bN028 (13.9)
 N116 (7.9)
Median length of follow-up, year (IQR)5 (2–10)
BCR, n (%)74 (39.2)
Median time to BCR, year (IQR)2 (1–7)
5-Year BCR-free survival (95% CI)0.603 (0.518–0.678)
10-Year BCR-free survival (95% CI)0.468 (0.367–0.562)
Metastasis, n (%)20 (10.6)
Median time to metastasis, year (IQR)5 (2–9)
5-Year metastasis-free survival (95% CI)0.918 (0.852–0.956)
10-Year metastasis-free survival (95% CI)0.816 (0.711–0.886)
Median PGA (IQR)3.74 (0.93–9.35)
Mean PGA5.85
Median PGA, high CNV only (IQR)0 (0,0)
Mean PGA, high CNV only0.45